![](/wp-content/uploads/2020/12/Merck-novo-announcement.jpg)
$599
Thoughts on Pediatric Exclusivity for Saxenda and Januvia
Two diabetes-related news items have been observed: late last week, FDA approved Saxenda for the treatment of obesity in adolescents (view press release); and FDA issued a press release stating the Januvia franchise has not been proven to improve glycemic control in pediatric patients (ages 10-17) with T2DM (view updated Januvia label). Below, FENIX provides thoughts on how the label updates are anticipated to impact the respective brands.